<DOC>
	<DOC>NCT01327183</DOC>
	<brief_summary>This randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of RO4905417 in patients with non ST-elevation myocardial infarction (Non-STEMI) undergoing percutaneous coronary intervention (PCI). Patients will be randomized to receive an intravenous infusion of either 5 mg/kg RO4905417 or 20 mg/kg RO4905417 or placebo before PCI. Follow-up will be for 4 months.</brief_summary>
	<brief_title>A Study of RO4905417 in Patients With Non ST-Elevation Myocardial Infarction (Non-STEMI) Undergoing Percutaneous Coronary Intervention</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<criteria>Adult patients, &gt;18 to &lt;75 years of age Non STelevation myocardial infarction Woman of childbearing potential will be allowed only if using two acceptable methods of contraception Body mass index (BMI) &lt;/= 40 kg/m2 Acute STelevation myocardial infarction (STEMI) Culprit coronary lesion with a total thrombotic occlusion or a lesion requiring the use of distal embolization protection or thrombectomy devices Percutaneous coronary intervention (PCI) within the past 72 hours Thrombolytic therapy within the past 7 days Major surgery within the past 3 months History of cerebral vascular disease or stroke in the past 3 months Bleeding disorders Inadequately controlled severe hypertension Prior coronary artery bypass graft (CABG) surgery Decompensated heart failure (oedema and/or rale) Acute infection at screening or active chronic infection within 3 months prior to PCI Patients known to be HIV positive, patients receiving antiretroviral drugs, or immunosuppressed patients Uncontrolled diabetes mellitus (HbA1C &gt;10%) at baseline</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>